Dr. Naveed Gulzar is a post-doctoral fellow at Simon Fraser University and is currently funded by a Michael Smith Foundation for Health Research post-doctoral fellowship. His research examines how the host immune system manages resources in chronic viral infections, such as the human immunodeficiency virus (HIV) and hepatitis C virus (HCV), in order to stem disease progression. His current focus lies in characterizing the development (and the challenges therein) of a neutralizing antibody response in HIV, HCV and dual infection (HIV/HCV) settings, in addition to developing vaccine-based strategies to elicit such responses in animal models of study.
Gulzar is a co-investigator on grants funded independently by the US National Institutes of Health and the Canadian Institutes for Health Research (CIHR) to develop DNA prime/protein-boost vaccine strategies to elicit anti-HIV antibodies using novel HIV envelope immunogens. He received his PhD in microbiology and immunology from the University of Ottawa, supported by a CIHR doctoral award, and upon graduation, was awarded a Natural Sciences and Engineering Research Council of Canada Industrial Research and Development Fellowship to support his research in developing novel therapeutic strategies targeting hemorrhagic fever viruses at a Vancouver-based biotechnology company. Gulzar is an author on more than 10 peer-reviewed publications and more than 50 conference proceedings.
University: Simon Fraser University
Department: Molecular Biology & Biochemistry
Position: Post-Doctoral Fellow
Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol. 2012 Mar;86(6):2930-41. doi: 10.1128/JVI.06349-11. Epub 2012 Jan 11. (PubMed abstract)
Gulzar N, Diker B, Balasubramanian S, Jiang JQ, Copeland KF. Human immunodeficiency virus-1 infection protects against a Tc1-to-Tc2 shift in CD8(+) T cells. Hum Immunol. 2011 Nov;72(11):995-1000. doi: 10.1016/j.humimm.2011.08.012. Epub 2011 Aug 28. (PubMed abstract)
Gulzar N, Diker B, Mihowich J, Deschatelets J, Arsenault ME, Lamoureux N, Cameron DW, Kim JE, Copeland KF. Proportion of HIV-1 infected CD8+CD4- T lymphocytes in vivo. Curr HIV Res. 2008 Nov;6(6):585-96. (PubMed abstract)
Gulzar N, Shroff A, Buberoglu B, Klonowska D, Kim JE, Copeland KF. Properties of HTLV-I transformed CD8+ T-cells in response to HIV-1 infection. Virology. 2010 Oct 25;406(2):302-11. doi: 10.1016/j.virol.2010.07.029. Epub 2010 Aug 13. (PubMed abstract)
Romanuik, S. F., Grist, S. M., Gray, B. L., Hohertz, D., Kavanagh, K., Gulzar, N., Scott, J. K., Nirwan, R., Hui, C., Brolo, A. G., and Gordon, R. Detecting antibodies secreted by trapped cells using extraordinary optical transmission. (2011). IEEE Sensors. 11(11): 2732 – 2739.